An overview of drug therapies used in the treatment of dystonia and spasticity in children

Archives of Disease in Childhood: Education and Practice Edition

Volumn 97, Issue 6, 2012, Pages 230-235

  Tickner, Neil ^a   Apps, John R ^a   Keady, Simon ^a   Sutcliffe, Alastair G ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BACLOFEN; BOTULINUM TOXIN A; DANTROLENE; DIAZEPAM; PHENOL; TIZANIDINE;

AGITATION; ATAXIA; BOTULISM; CATHETER COMPLICATION; CEREBRAL PALSY; CONFUSION; CONSTIPATION; DELUSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSTONIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HEMATOMA; HEPATITIS; HUMAN; HYPERPYREXIA; HYPERSALIVATION; HYPOTENSION; INCONTINENCE; INFECTION; INJECTION SITE PAIN; INSOMNIA; LIQUORRHEA; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MORNING DOSAGE; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE TWITCH; NAUSEA; PARALYSIS; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; SYSTEMIC THERAPY; WEAKNESS; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; CEREBRAL PALSY; CHILD; DYSTONIA; GABA ANTAGONISTS; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY;

EID: 84869888646     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301170     Document Type: Review

References (22)

1. Dan B, Motta F, Vles JSH. Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol 2010;14:19-28.
2. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42:816-24.
3. Sanger TD, Delgado MR, Gaebler-Spira D, et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:89-97.
4. British National Formulary for Children. 2011-2012 Edition.
5. Delgado MR, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74:336-43.
6. Verotti A, Greco R, Spalice A, et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34:1-6.
7. Shou M, Mei Q, Ettore MW, et al. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 1999;340:845-53.
8. Qin X-P, Xie HG, Wang W, et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999;66:642-6.
9. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
10. Chung Y-C, Chen C-L, Wong A. Pharmacotherapy of spasticity in children with cerebral palsy. J Formos Med Assoc 2011;110:215-22.
11. Wiersma HE, van Boxtel CJ, Butter JJ, et al. Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. Ther Drug Monit 2003;25:93-8.
12. Knuttson E, Lindblom U, Martenssson A. Plasma and cerebrospinal fluid levels of baclofen at optimal therapeutic responses in spastic paralysis. J Neurol Sci 1974;23:473-84.
13. Lubsch L, Habersang R, Haase M, et al. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol 2006;21:1090-2.
14. CSM Current Problems in Pharmacovigilance. February 1997.
15. Summary of Product Characteristics. Tizanidine (Zanaflex®). http://www.medicines.org.uk/emc/medicine/16842/SPC/ (accessed 15 Jan 2012).
16. Vasquez-Briceno A, Arellano-Saldana ME, Leon-Hernandez SR, et al. The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy. Rev Neurol 2006;43:132-6.
17. FDA Drug Safety Alert. April 2002. http://www.fda.gov/downloads/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM170907.pdf
18. Summary of Product Characteristics. Botox® . http://www.medicines. org.uk/emc/medicine/16842/SPC/ (accessed 15 Jan 2012).
19. Summary of Product Characteristics. Dysport® . http://www.medicines. org.uk/emc/medicine/16842/SPC/ (accessed 15 Jan 2012).
20. Tilton A, Vargus-Adams J, Delgardo M. Pharmacologic treatment of spasticity in children. Semin Pediatr Neurol 2010;17:261-7.
21. Heinan F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010;14:45-66.
22. National Institute for Health and Clinical Excellence: Draft consultation "Spasticity in children and young people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and their early musculoskeletal complications", October 2011. http://www.nice.org.uk/ nicemedia/live/12218/56763/56763.pdf (accessed 2 Aug 2012).